Skip to main content
Premium Trial:

Request an Annual Quote

Cypher Genomics, U Penn to Collaborate on Genetics Study of Progressive Supranuclear Palsy

NEW YORK (GenomeWeb) – Cypher Genomics today announced a collaboration with the University of Pennsylvania to investigate the genetic causes of progressive supranuclear palsy. 

CurePSP is funding the research with a grant for an undisclosed amount. 

Headed by Gerard Schellenberg, a professor of pathology and laboratory medicine in the Perelman School of Medicine at U Penn, the CurePSP Genetics Consortium will collect and analyze exome sequencing data from more than 700 PSP patients and their close family members. The goal is to identify possible genetic factors and biomarkers to better understand the mechanisms of the disease and discover novel targets for future drug development and potentially new diagnostics, Cypher said. 

The work will use Cypher's Mantis technology and know-how for analysis of whole-exome sequencing data. The Mantis technology provides rapid, automated genome interpretation at scale for identifying disease genes, as well as for population-based studies, diagnostic development, and biomarker development, the San Diego-based company said. 

PSP is a neurodegenerative brain ailment that affects nerve cells that control walking, balance, mobility, vision, speech, and swallowing. It has no known cause, treatment, or cure.